EverQuote, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
EVER$28.03-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities: | |||
| Net income (loss) | $99,311 | $32,169 | $(51,287) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization expense | 3,811 | 5,672 | 6,196 |
| Stock-based compensation expense | 24,299 | 20,614 | 24,096 |
| Deferred taxes | (38,428) | — | — |
| Loss on sale of health assets | — | — | 19,388 |
| Impairment of right-of-use asset | — | — | 384 |
| Change in fair value of contingent consideration liabilities | — | — | (150) |
| Provision for bad debt | 10 | 13 | 204 |
| Unrealized foreign currency transaction (gains) losses | 110 | (26) | 21 |
| Litigation accrual settled with sale of assets | 7,841 | — | — |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (13,813) | (40,178) | 8,219 |
| Prepaid expenses and other current assets | (4,440) | 440 | 962 |
| Commissions receivable, current and non-current | 1,873 | 4,880 | 4,176 |
| Operating lease right-of-use assets | 1,124 | 2,213 | 2,497 |
| Other assets | 137 | (291) | 421 |
| Accounts payable | 16,887 | 42,664 | (13,411) |
| Accrued expenses and other current liabilities | (2,105) | 1,040 | (1,543) |
| Deferred revenue | (103) | (107) | 5 |
| Operating lease liabilities | (1,133) | (2,537) | (3,006) |
| Net cash provided by (used in) operating activities | 95,381 | 66,566 | (2,828) |
| Cash flows from investing activities: | |||
| Acquisition of property and equipment, including costs capitalized for development of internal-use software | (5,057) | (4,114) | (3,840) |
| Proceeds from sale of health assets | — | — | 13,194 |
| Net cash provided by (used in) investing activities | (5,057) | (4,114) | 9,354 |
| Cash flows from financing activities: | |||
| Proceeds from exercise of stock options | 3,931 | 3,553 | 979 |
| Repurchase of common stock | (21,024) | — | — |
| Tax withholding payments related to net share settlement | (3,971) | (1,846) | (402) |
| Net cash provided by (used in) financing activities | (21,064) | 1,707 | 577 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 3 | 1 | 18 |
| Net increase in cash, cash equivalents and restricted cash | 69,263 | 64,160 | 7,121 |
| Cash, cash equivalents and restricted cash at beginning of period | 102,116 | 37,956 | 30,835 |
| Cash, cash equivalents and restricted cash at end of period | $171,379 | $102,116 | $37,956 |
| Supplemental disclosure of noncash investing and financing information: | |||
| Acquisition of property and equipment included in accounts payable | $125 | $135 | $25 |
| Assets sold in settlement of litigation accrual | $8,141 | $— | $— |
| Operating lease liabilities arising from obtaining right-of-use assets | $— | $4,026 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.